Fingolimod Modulates Dendritic Architecture in a BDNF-Dependent Manner.

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Brain-derived neurotrophic factor (BDNF) is vital for brain development and function.
• Altered BDNF levels are linked to cognitive deficits in neurological diseases.
• Fingolimod, a sphingosine-1-phosphate receptor agonist, is explored for boosting BDNF.

Purpose of the Study:

• To elucidate the cellular mechanisms of Fingolimod's therapeutic effects, focusing on BDNF.
• To investigate Fingolimod's impact on neuronal structure and activity markers.
• To assess Fingolimod's potential in mitigating structural abnormalities in neurodevelopmental disorders.

Main Methods:

• Primary hippocampal and cortical neuron cultures.
• Assessment of dendritic architecture, spine density, and morphology.
• Analysis of c-Fos and pERK1/2 protein expression.
• Evaluation of neurite architecture in mutant mouse models (Mecp2 and Cdkl5).

Main Results:

• Fingolimod modulates dendritic architecture and spine characteristics in mature neurons.
• Fingolimod upregulates activity-related proteins c-Fos and pERK1/2.
• BDNF release is essential for Fingolimod's observed effects.
• Fingolimod rescues neurite architecture abnormalities in Rett syndrome and Cdk5 deficiency models.

Conclusions:

• Fingolimod exerts therapeutic effects through BDNF-dependent mechanisms.
• The drug influences neuronal structure and activity, offering potential for neurological disorders.
• Fingolimod demonstrates promise in correcting structural deficits in neurodevelopmental conditions.